Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO) in a Pediatric Population. Open Label, Randomized, Active Controlled, Phase 3 Study.

Trial Profile

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO) in a Pediatric Population. Open Label, Randomized, Active Controlled, Phase 3 Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs IC 51 (Primary) ; Hepatitis A vaccine inactivated; Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Japanese encephalitis
  • Focus Adverse reactions; Registrational
  • Sponsors Intercell
  • Most Recent Events

    • 24 Apr 2017 Results published in the Pediatric Infectious Disease Journal
    • 19 Apr 2017 Results assessing immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine in subgroup of patients (n=496), published in the Pediatric Infectious Disease Journal
    • 21 Jun 2013 Results from this trial were used to support new US recommendations for use of the vaccine in children, according to a Valneva media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top